CRKL Antibody

What is CRKL and why is it significant in research?

CRKL (CRK-like proto-oncogene, adaptor protein) is a 33.8 kDa protein belonging to the CRK protein family that mediates the transduction of intracellular signals . The canonical human protein consists of 303 amino acid residues . CRKL has gained significant research importance due to its role in cancer, particularly chronic myeloid leukemia (CML), where it acts as a substrate for the BCR-ABL fusion protein . Additionally, CRKL contains one SH2 domain and two SH3 domains that enable protein-protein interactions and signal transduction , making it a crucial component in multiple signaling pathways that influence cellular responses to growth factors and other stimuli.

What are the typical molecular weights observed for CRKL in Western blots?

While the canonical CRKL protein has a predicted molecular weight of 34 kDa, researchers often observe bands at different molecular weights depending on the experimental conditions and cell types:

• 37 kDa in Jurkat, BaF3, and Rat-2 cell lines

• 39 kDa in K562, A431, and Jurkat cell lines

• 43-44 kDa in various human, mouse, and rat cell lines

This variability is likely due to post-translational modifications, particularly phosphorylation events that cause mobility shifts during electrophoresis. When designing experiments, it's important to verify the expected band size for your specific cell line and experimental conditions.

What experimental applications are CRKL antibodies suitable for?

CRKL antibodies have been validated for multiple research applications:

When selecting an antibody, confirm that it has been validated for your specific application and target species.

How should I validate the specificity of a CRKL antibody?

Proper antibody validation is critical for reliable research results. For CRKL antibodies, consider the following validation approaches:

• Knockout/knockdown controls: Use CRKL knockout cell lines (like the CRKL knockout HeLa cell line) as negative controls . The absence of signal in knockout samples confirms antibody specificity.

• Multiple antibody approach: Use at least two different antibodies targeting distinct epitopes of CRKL and compare the results.

• Phospho-specificity validation: For phospho-specific antibodies (e.g., pCRKL Tyr207), treat samples with phosphatase to confirm the phospho-specificity of the observed signal.

• Species cross-reactivity: When working with non-human samples, confirm cross-reactivity with your species of interest. Many CRKL antibodies react with human, mouse, and rat CRKL .

• Loading controls: Always include appropriate loading controls (e.g., alpha-tubulin, GAPDH) to normalize CRKL expression levels .

What are the recommended protocols for detecting CRKL by Western blot?

For optimal Western blot results with CRKL antibodies:

• Sample preparation:

  • Extract total protein from cells using standard lysis buffers (RIPA or similar)

  • For phosphorylated CRKL detection, include phosphatase inhibitors in your lysis buffer

• Gel electrophoresis:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Load 20-30 μg of total protein per lane

• Transfer and blocking:

  • Transfer to PVDF membrane (recommended over nitrocellulose for CRKL)

  • Block with 5% BSA in TBST (preferred for phospho-protein detection) or 5% non-fat milk

• Antibody incubation:

  • Primary antibody: Dilute according to manufacturer's recommendation (typically 1:1000)

  • Incubate overnight at 4°C for best results

  • Secondary antibody: HRP-conjugated anti-species IgG (typically 1:10000-1:20000)

• Detection:

  • Enhanced chemiluminescence (ECL) works well for most CRKL antibodies

  • For phospho-CRKL detection, consider more sensitive detection methods

• Analysis:

  • For quantifying pCRKL/CRKL ratios, scan blots and measure band intensities with appropriate software

  • The coefficient of variability for pCRKL/CRKL ratio determination is approximately 14% (range: 3-22%)

How can I monitor phosphorylated CRKL as a biomarker for BCR-ABL activity?

CRKL phosphorylation (particularly at Tyr207) serves as an established biomarker for BCR-ABL kinase activity in CML patients:

• Sample collection:

  • Peripheral blood leukocytes are adequate for most analyses

  • Process samples promptly to preserve phosphorylation status

• Western blot approach:

  • Use anti-CRKL antibodies that detect both phosphorylated and unphosphorylated forms

  • These forms can be separated by band shift on SDS-PAGE

  • Calculate the pCRKL/total CRKL ratio by densitometric analysis

  • A decreased ratio indicates successful BCR-ABL inhibition

• Baseline considerations:

  • Establish baseline pCRKL/CRKL ratios before treatment

  • Note that baseline ratios differ between CML and Ph+ acute lymphoblastic leukemia

• Treatment monitoring:

  • Sequential monitoring of pCRKL/CRKL ratios can reveal early signs of resistance to tyrosine kinase inhibitors

  • Rapid BCR-ABL reactivation is indicated by increasing pCRKL/CRKL ratios

This approach has been successfully used in clinical trials of nilotinib and other BCR-ABL inhibitors to assess treatment efficacy .

What is the role of CRKL in T cell migration and immune responses?

Recent research has identified CRKL as a crucial regulator of T cell migration, with important implications for immune responses:

This research suggests that targeting CrkL or its binding partners could potentially be used to control T cell trafficking in inflammatory diseases and for designing adoptive T cell therapies .

What is circCRKL and how does it relate to CRKL protein studies?

circCRKL is a circular RNA derived from the CRKL gene, which has emerged as an important regulatory molecule in cancer:

• Structure and origin:

  • circCRKL is a 466-nucleotide circular RNA back-spliced from exon 2 of the CRKL gene

  • It is stable (resistant to RNase R degradation) and has a longer half-life than linear CRKL mRNA

  • Primarily located in the cytoplasm of cancer cells

• Disease relevance:

  • Highly expressed in chronic myeloid leukemia patients compared to normal donors

  • Significantly upregulated in BCR-ABL-positive cell lines

  • Functions as an oncogenic circRNA in CML but is downregulated in other cancers like prostate cancer and AML, indicating cancer-specific and cell type-specific expression patterns

• Molecular mechanism:

  • Acts as a microRNA sponge for miR-877-5p to enhance BCR-ABL expression levels

  • Knockdown of circCRKL inhibits proliferation of BCR-ABL-positive cells and increases their sensitivity to imatinib

• Research implications:

  • When studying CRKL in BCR-ABL-positive leukemias, consider the regulatory role of circCRKL

  • Targeting circCRKL along with tyrosine kinase inhibitors represents a potential novel therapeutic strategy for CML patients

These findings highlight the complex interplay between coding and non-coding RNAs derived from the CRKL gene and their respective roles in cancer biology.

How is CRKL implicated in gastric cancer research?

Beyond its established role in leukemia, CRKL has emerged as a potential therapeutic target in solid tumors:

• Genomic alterations:

  • Genome-wide SNP microarray analysis has identified CRKL as a highly amplified gene in gastric cancer

  • CRKL protein expression can be evaluated using immunohistochemistry with intensity values determined on a 4-point scale

• Therapeutic approaches:

  • CRKL-targeting peptides have been developed to disrupt protein complexes involving CRKL's SH3 domain

  • These peptides contain:

    • A shuttle tag sequence (KKW KMR RNP FWI KIQ RC) for receptor-independent cell entry

    • A targeting sequence that disrupts protein-protein interactions

  • Cell viability and proliferation assays (MTT assay) have been used to assess the effect of these peptides

• Technical considerations:

  • CRKL-targeting peptides are typically synthesized using reverse-phase HPLC

  • Stock solutions are prepared in DMSO and stored at -80°C

  • Final DMSO concentration in experiments should be limited to 0.2%

This research direction illustrates how CRKL antibodies can be used not only to detect the protein but also to validate the effects of novel therapeutic approaches targeting CRKL-dependent signaling.

Why might I observe different molecular weights for CRKL in Western blots?

The variability in observed molecular weights for CRKL is a common issue that can be attributed to several factors:

• Post-translational modifications:

  • Phosphorylation of CRKL (particularly at Tyr207) causes a mobility shift in SDS-PAGE

  • This can result in observed molecular weights of 37-44 kDa despite the predicted 34 kDa size

• Technical variables:

  • Different gel percentages and running conditions affect protein migration

  • Various molecular weight markers may be calibrated differently

  • Different buffer systems can influence apparent molecular weight

• Detection system variations:

  • Simple Western™ system shows CRKL at approximately 44 kDa

  • Traditional Western blot may show CRKL at 37-39 kDa

• Species-specific differences:

  • Human CRKL may migrate slightly differently than mouse or rat CRKL

  • In some experiments, human CRKL appears at 44 kDa while mouse/rat CRKL appears at 43 kDa

To address this issue, always include positive controls from well-characterized cell lines (e.g., K562, Jurkat) to establish the expected molecular weight in your experimental system.

What factors affect the reliability of pCRKL/CRKL ratio measurements?

The pCRKL/CRKL ratio is an important biomarker for BCR-ABL activity, but several factors can influence its reliability:

• Technical variability:

  • Coefficient of variability (CV) for pCRKL/CRKL ratio determination is approximately 14% (range: 3-22%)

  • Standardize protocols to minimize variation

• Sample handling:

  • Delayed processing can lead to dephosphorylation

  • Phosphatase inhibitors must be included in all buffers

  • Rapid freezing of samples is recommended if immediate processing is not possible

• Disease stage effects:

  • Baseline pCRKL/CRKL ratios can differ significantly between:

    • Chronic phase CML

    • Accelerated phase CML

    • Blast crisis CML

    • Ph+ acute lymphoblastic leukemia

  • These differences must be considered when interpreting results

• Treatment effects:

  • Dynamic changes occur during treatment with tyrosine kinase inhibitors

  • Rapid reactivation can occur, particularly in patients with P-loop mutations (Y253H, E255K) or T315I mutation

  • Sequential monitoring is more informative than single time points

To improve reliability, establish baseline values for each patient, use multiple time points for monitoring, and maintain consistent experimental conditions across all measurements.

How can I resolve non-specific binding issues with CRKL antibodies?

Non-specific binding is a common challenge when working with antibodies. For CRKL antibodies specifically:

• Antibody validation:

  • Use CRKL knockout cells as negative controls to identify non-specific bands

  • Verify results with multiple antibodies targeting different epitopes

• Blocking optimization:

  • For phospho-CRKL detection, use 5% BSA in TBST rather than milk

  • For total CRKL, compare results with both milk and BSA blocking

  • Consider adding 0.1-0.5% Tween-20 to reduce non-specific binding

• Antibody concentration:

  • Titrate primary antibody concentration (typically 1:500-1:2000)

  • Higher concentrations often increase background and non-specific binding

  • Follow manufacturer's recommendations for starting dilutions

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Consider using fluorescent secondaries for multiplexing and better quantification

  • Anti-Goat IgG secondary antibodies work well for many CRKL antibodies

• Sample preparation:

  • Ensure complete cell lysis and proper protein denaturation

  • For tissues, optimize extraction protocols to reduce contaminating proteins

By systematically addressing these factors, you can significantly improve the specificity of CRKL detection in your experiments.

What are emerging areas of CRKL research beyond cancer biology?

While CRKL has been extensively studied in the context of cancer, particularly leukemia, several emerging research directions are expanding our understanding of CRKL's functions:

• T cell immunology:

  • CRKL's unique role in T cell migration opens new avenues for immunotherapy research

  • Potential applications in controlling inflammatory responses and enhancing T cell-based therapies

  • Investigation of CRKL binding partners in T cell signaling pathways

• Non-coding RNA networks:

  • The discovery of circCRKL highlights the complex regulatory networks involving coding and non-coding RNAs

  • Further exploration of how these networks influence disease progression and treatment response

  • Potential for RNA-based therapeutic approaches targeting CRKL-related pathways

• Signaling pathway integration:

  • CRKL's role as an adaptor protein positions it at the intersection of multiple signaling pathways

  • Investigation of how CRKL integrates signals from different receptors and influences cellular decisions

  • Development of computational models to predict CRKL-dependent signaling outcomes

These emerging areas suggest that CRKL research will continue to expand beyond its traditional focus on oncology, with potential implications for immunology, RNA biology, and systems biology approaches to understanding cellular signaling.

How can advanced techniques enhance CRKL research?

Recent technological advances offer new opportunities for studying CRKL biology:

• CRISPR-Cas9 gene editing:

  • Creation of precise CRKL knockout and knockin models

  • Engineering of specific mutations to study structure-function relationships

  • Development of conditional knockout systems to study tissue-specific roles

• Proximity labeling proteomics:

  • BioID or APEX2-based approaches to identify CRKL-interacting proteins in living cells

  • Time-resolved analysis of signaling complex formation

  • Cell type-specific interaction networks

• Super-resolution microscopy:

  • Visualization of CRKL-containing signaling complexes at the nanoscale

  • Dynamic imaging of CRKL recruitment during cell migration and immune synapse formation

  • Colocalization studies with potential binding partners

• Single-cell analysis:

  • Examination of CRKL expression and phosphorylation heterogeneity within cell populations

  • Correlation of CRKL status with cell phenotypes and treatment responses

  • Integration with other single-cell omics approaches